Lawsuits claim Tylenol use in pregnancy causes autism

02 ottobre 2025 Riportato dall'IA

More than 100 lawsuits have been filed against acetaminophen manufacturers, including Johnson & Johnson, alleging that the drug's use during pregnancy increases the risk of autism and ADHD in children. These legal actions stem from scientific studies showing associations between prenatal exposure and neurodevelopmental disorders. The cases highlight growing concerns over the safety of a widely used pain reliever.

FDA Approves Subcutaneous Version of Merck's Keytruda

The U.S. Food and Drug Administration has approved Merck's Keytruda Qlex, a subcutaneous formulation of the cancer drug pembrolizumab, for use in adults across most solid tumor indications. Announced on September 19, 2025, this new injectable version offers a quicker administration time compared to the traditional intravenous method, potentially enhancing patient convenience and access to treatment. The approval highlights efforts to innovate drug delivery in oncology amid growing demands for efficient therapies.

AstraZeneca Cuts Prices on Select US Drugs After Trump Pressure

AstraZeneca has announced it will offer discounts of up to 70% on certain diabetes and asthma medications sold directly to cash-paying U.S. patients, responding to demands from President Donald Trump for lower drug prices. The move aligns these prices with those paid by Medicare and marks the company as the latest in the pharmaceutical industry to adjust amid ongoing regulatory scrutiny. This development underscores the intensifying focus on drug affordability in the United States under the current administration.

Pfizer stock rises after aligning with Trump on drug pricing

01 ottobre 2025 Riportato dall'IA

Pfizer's shares climbed on Monday after the company expressed support for former President Donald Trump's proposal to allow imports of lower-priced drugs from Canada. This stance marks a shift for the pharmaceutical giant, which has historically opposed such measures. The move comes amid ongoing debates over U.S. drug costs.